About CellXchange
Zahra Mazidi, Ph.D. Candidate
Founder of CellXchange Innovation e.U.
Biotechnologist & Ph.D. Researcher focused on ethical, cell-based drug discovery and regenerative innovation..
Explore CellXchange Innovations e.U.’s Commitment and Aspirations
CellXchange Innovation e.U. was founded and is led by Zahra Mazidi, an accomplished biotechnologist and Ph.D. researcher dedicated to transforming drug discovery through advanced cellular technologies.
👩‍🔬 About Zahra Mazidi
- Ph.D. Candidate at Evercyte GmbH (Vienna, Austria)
Zahra’s doctoral work is part of the prestigious Marie Skłodowska-Curie IN³ programme. Her research integrates iPSC-derived vascular models and cutting-edge toxicology to drive innovation in early-stage drug development, with a strong emphasis on ethical, animal-free methodologies researchgate.net+6at.linkedin.com+6hilarispublisher.com+6hilarispublisher.com. - Managing Shareholder of Juvenile GmbH
In this leadership role, Zahra applies her scientific expertise to steer biotech innovation in translational therapies and cell-based technologies at.linkedin.com+1linkedin.com+1. - Expertise & Contributions
- Designed in vitro models using iPSC-derived endothelial cells to study vascular toxicity (e.g., Cyclosporin A effects) researchgate.net+2hilarispublisher.com+2proceedings.altex.org+2.
- Specialized in extracellular vesicle (EV) production pipelines, including telomerase-enhanced MSC lines for scalable and functional EV generation srbevs.rs.
- Active contributor to international biotech forums such as the European Stem Cell Congress and ISEV, collaborating across Europe to accelerate non-animal drug testing strategies at.linkedin.com+3onlinelibrary.wiley.com+3pmc.ncbi.nlm.nih.gov+3.
🚀 Our Vision & Mission
At CellXchange Innovation, we combine Zahra’s deep scientific roots with a passion for sustainable biotech to:
- Develop animal-free, cell-based platforms for early drug discovery and toxicological assessment.
- Standardize scalable EV-based delivery systems, leveraging Zahra’s work in telomerized MSC-EVs for regenerative and therapeutic applications.
- Bridge academic excellence and industrial impact, moving revolutionary research into practical, high-throughput biotech solutions.
🤝 Why Choose Us
Collaborative spirit, fostered through interdisciplinary partnerships and core participation in European biotech networks.
Cutting-edge science grounded in peer-reviewed research and Marie Skłodowska-Curie training.
Ethical innovation with fully validated in vitro systems, eliminating animal use without compromising rigor.
